Uterine leiomyosarcoma (uLMS) represents a rare gynecological malignancy with high incidence of recurrence. Evidence in literature about the management of recurrent uLMS is limited, and the role of secondary cytoreduction has been evaluated in small and heterogeneous populations. The objective of this study is to assess the prognostic role of secondary cytoreductive surgery and its related complications in a large and homogeneous group of patients.
Secondary cytoreductive surgery in recurrent uterine leiomyosarcoma: a multi-institutional study / Bizzarri N, Ghirardi V, Di Fiore GLM, De Iaco P, Gadducci A, Casarin J, Perrone AM, Pasciuto T, Scambia G, Fagotti A. - In: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. - ISSN 1048-891X. - ELETTRONICO. - 29:7(2019), pp. 1134-1140. [10.1136/ijgc-2019-000355]
Secondary cytoreductive surgery in recurrent uterine leiomyosarcoma: a multi-institutional study
Bizzarri N;Ghirardi V;De Iaco P;Perrone AM;
2019
Abstract
Uterine leiomyosarcoma (uLMS) represents a rare gynecological malignancy with high incidence of recurrence. Evidence in literature about the management of recurrent uLMS is limited, and the role of secondary cytoreduction has been evaluated in small and heterogeneous populations. The objective of this study is to assess the prognostic role of secondary cytoreductive surgery and its related complications in a large and homogeneous group of patients.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
